ONCOGENE EXPRESSION IN HUMAN CARCINOMAS
人类癌症中癌基因的表达
基本信息
- 批准号:4691890
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
Monoclonal antibodies (MAbs) of predefined specificity have been generated
by utilizing a synthetic peptide reflecting amino acid positions 10-17 of
the Hu-rasT24 gene product as immunogen. When paraffin-embedded
Formalin-fixed tissue sections and the avidin-biotin complex
immunoperoxidase methods were used, the RAP (RA, ras; P, peptide) MAbs
clearly defined enhanced ras p21 expression in the majority of human colon
and mammary carcinomas. The majority of all abnormal ducts and lobules
from fibroadenoma and fibrocystic disease patients were negative, as well
as normal mammary and colonic epithelia examined.
We have used the RAP MAbs to define ras p21 protein expression in a
spectrum of clonic disease states. Immunohistochemical analyses of
individual cells within tissue sections reveal differences in ras p21
expression in colon carcinomas compared with normal colonic epithelium,
benign colon tumors and inflammatory or dysplastic colon lesions. Our data
suggest that ras p21 expression is correlated with depth of carcinoma
within the bowel wall, and is probably a relatively late event in colon
carcinogenesis.
We have recently developed a quantitative lequid competition RIA for ras
p21 using MAb Y13259. By the use of a standard of pure recombinant ras
p21, we are now able to detect p21 at fM levels, and to determine the
number of molecules of p21 per cell. The concomitant use of this
quantitative RIA and immunohistochemical analyses of normal, dysplastic and
inflammatory disease states, as well as carcinomas, should lead to a better
understanding of the role of the ras gene in the genesis of these lesions.
已经产生了预定义特异性的单克隆抗体(mab)
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
P H HAND其他文献
P H HAND的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('P H HAND', 18)}}的其他基金
PARAMETERS INVOLVED IN THE TUMOR TARGETING OF MONOCLONAL ANTIBODIES
单克隆抗体肿瘤靶向涉及的参数
- 批准号:
3813408 - 财政年份:
- 资助金额:
-- - 项目类别:
PARAMETERS INVOLVED IN THE TUMOR TARGETING OF MONOCLONAL ANTIBODIES
单克隆抗体肿瘤靶向涉及的参数
- 批准号:
3916372 - 财政年份:
- 资助金额:
-- - 项目类别:
相似海外基金
Pathology of Breast Neoplasms determined by MRS
MRS 测定乳腺肿瘤的病理学
- 批准号:
nhmrc : 950215 - 财政年份:1995
- 资助金额:
-- - 项目类别:
NHMRC Project Grants














{{item.name}}会员




